Gastrointestinal acute graft-versus-host disease in children: Histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1590-1599

  Calkoen, Friso G J ^a   Jol van der Zijde, Cornelia M ^a   Mearin, M Luisa ^a   Schweizer, Joachim J ^a   Jansen Hoogendijk, Anja M ^a   Roelofs, Helene ^a   van Halteren, Astrid G S ^a   Egeler, R Maarten ^a,b   van Tol, Maarten J D ^a   Ball, Lynne M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute graft versus host disease; Biomarkers; Children; Gastrointestinal; Histology; Mesenchymal stromal cells

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CELL DAMAGE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; ENDOTHELIUM CELL; FEMALE; GASTROINTESTINAL BIOPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE VILLUS ATROPHY; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MESENCHYMAL STROMA CELL; MYELOABLATIVE CONDITIONING; PREDICTION; PROGNOSIS; PROPHYLAXIS; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SURVIVAL; TISSUE INJURY; TREATMENT RESPONSE;

ACUTE GRAFT-VERSUS-HOST DISEASE; BIOMARKERS; CHILDREN; GASTROINTESTINAL; HISTOLOGY; MESENCHYMAL STROMAL CELLS;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL NEOPLASMS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885826097     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.08.006     Document Type: Article

References (41)

1. Couriel D., Caldera H., Champlin R., et al. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101:1936-1946.
2. Goker H., Haznedaroglu I.C., Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001, 29:259-277.
3. Ball L.M., Egeler R.M. Acute GVHD: pathogenesis and classification. Bone Marrow Transplant 2008, 41(Suppl 2):S58-S64.
4. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
5. Davies S.M., Wang D., Wang T., et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2009, 15:360-366.
6. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
7. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
8. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
9. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
10. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
11. Prasad V.K., Lucas K.G., Kleiner G.I., et al. Efficacy and safety of exvivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
12. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
13. Lucchini G., Introna M., Dander E., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
14. Martin P.J., Uberti J.P., Soiffer R.J. Prochymal improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GVHD [abstract]. Biol Blood Marrow Transplant 2010, 16:S169-S170.
15. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
16. Ball L., Bredius R., Lankester A., et al. Third-party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia 2008, 22:1256-1257.
17. Ciccocioppo R., Bernardo M.E., Sgarella A., et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011, 60:788-798.
18. Duijvestein M., Vos A.C., Roelofs H., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
19. Paczesny S., Krijanovski O.I., Braun T.M., et al. Abiomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
20. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013, 121:585-594.
21. Ferrara J.L., Harris A.C., Greenson J.K., et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118:6702-6708.
22. Luft T., Conzelmann M., Benner A., et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007, 110:4535-4542.
23. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
24. Paczesny S., Braun T.M., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010, 2:13ra2.
25. Washington K., Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 2009, 40:909-917.
26. Echavarria M., Forman M., van Tol M.J., et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001, 358:384-385.
27. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
28. Harris A.C., Ferrara J.L., Braun T.M., et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119:2960-2963.
29. Ertault-Daneshpouy M., Leboeuf C., Lemann M., et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood 2004, 103:4681-4684.
30. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
31. Perfetti P., Carlier P., Strada P., et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008, 42:609-617.
32. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
33. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid-refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
34. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010, 45:1347-1351.
35. Jitschin R., Mougiakakos D., von Bahr L., et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation. Stem Cells 2013, 31(8):1715-1725.
36. von Bahr L., Sundberg B., Lonnies L., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012, 18:557-564.
37. Dander E., Lucchini G., Vinci P., et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the invivo biological effect through patient immune monitoring. Leukemia 2012, 26:1681-1684.
38. Vossen J.M., Heidt P.J., van den Berg H., et al. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990, 9:14-23.
39. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-118.
40. Rodriguez-Otero P., Porcher R., de Peffault L.R., et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 2012, 119:5909-5917.
41. Landfried K., Zhu W., Waldhier M.C., et al. Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood 2011, 118:6971-6974.